Llaó Jordina, Naves Juan E, Ruiz-Cerulla Alexandra, Marín Laura, Mañosa Míriam, Rodríguez-Alonso Lorena, Cabré Eduard, Garcia-Planella Esther, Guardiola Jordi, Domènech Eugeni
Hospital de la Santa Creu i Sant Pau (Barcelona), Universitat Autònoma de Barcelona, Catalonia, Spain.
Hospital Universitari Germans Trias i Pujol (Badalona), CiberEHD, Catalonia, Spain.
J Crohns Colitis. 2014 Nov;8(11):1523-8. doi: 10.1016/j.crohns.2014.06.010. Epub 2014 Jul 22.
Oral corticosteroids remain the mainstay of treatment for moderately active ulcerative colitis (UC). In patients who fail to respond to oral corticosteroids, attempting the intravenous route before starting rescue therapies is an alternative, although no evidence supports this strategy.
To evaluate clinical outcomes after a course of intravenous corticosteroids for moderate attacks of UC according to the failed oral corticosteroids or not.
All episodes of active UC admitted to three university hospitals between January 2005 and December 2011 were identified and retrospectively reviewed. Only moderately active episodes treated with intravenous corticosteroids were included. Treatment outcome was compared between episodes which failed to outpatient oral corticosteroids for the index flare and those directly treated by intravenous corticosteroids.
110 episodes were included, 45% of which failed to outpatient oral corticosteroids (median dose 60mg/day [IQR 50-60], median length of course 10days [IQR 7-17]). Initial response (defined as mild severity or inactive disease at day 7 after starting intravenous corticosteroids, without rescue therapy) was achieved in 75%, with no between-group differences (78% vs. 75%). After a median follow-up of 12months (IQR 4-24), 35% of the initial responders developed steroid-dependency and up to 13% required colectomy. Unsuccessful response to oral corticosteroids was the only factor associated with steroid-dependency in the long term (P=0.001).
Intravenous corticosteroids are efficient for inducing remission in moderately active UC unresponsive to oral corticosteroids, but almost half of these patients develop early steroid-dependency. Alternative therapeutic strategies should be assessed in this clinical setting.
口服糖皮质激素仍然是中度活动性溃疡性结肠炎(UC)治疗的主要手段。对于口服糖皮质激素治疗无效的患者,在开始挽救治疗前尝试静脉途径给药是一种选择,尽管尚无证据支持这一策略。
根据口服糖皮质激素治疗是否失败,评估静脉注射糖皮质激素治疗UC中度发作后的临床结局。
确定并回顾性分析2005年1月至2011年12月期间三家大学医院收治的所有活动性UC发作病例。仅纳入接受静脉注射糖皮质激素治疗的中度活动性发作病例。比较对门诊口服糖皮质激素治疗指数发作无效的病例与直接接受静脉注射糖皮质激素治疗的病例的治疗结局。
共纳入110例发作病例,其中45%对门诊口服糖皮质激素治疗无效(中位剂量60mg/天[四分位间距50 - 60],中位疗程10天[四分位间距7 - 17])。75%的患者实现了初始缓解(定义为开始静脉注射糖皮质激素后第7天病情为轻度或疾病不活动,无需挽救治疗),组间无差异(78%对75%)。中位随访12个月(四分位间距4 - 24)后,35%的初始缓解者出现激素依赖,高达13%的患者需要行结肠切除术。长期来看,口服糖皮质激素治疗无效是与激素依赖相关的唯一因素(P = 0.001)。
静脉注射糖皮质激素对口服糖皮质激素无反应的中度活动性UC诱导缓解有效,但这些患者中几乎一半会早期出现激素依赖。在此临床背景下应评估替代治疗策略。